PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-20.40%
Negative net income growth while AGEN stands at 34.53%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
5.37%
Less D&A growth vs. AGEN's 18.49%, reducing the hit to reported earnings. David Dodd would confirm that core assets remain sufficient.
42.67%
Lower deferred tax growth vs. AGEN's 98.79%, implying fewer future tax liabilities. David Dodd would confirm there’s no short-term tax shock instead.
-15.52%
Both cut yoy SBC, with AGEN at -47.02%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
2.45%
Slight usage while AGEN is negative at -163.10%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-64.66%
Both negative yoy AP, with AGEN at -163.60%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
389.89%
Growth well above AGEN's 62.63%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
-15.52%
Negative yoy while AGEN is 182.81%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-26.74%
Negative yoy CFO while AGEN is 7.97%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
51.76%
CapEx growth well above AGEN's 90.37%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative yoy purchasing while AGEN stands at 0.00%. Joel Greenblatt sees a near-term liquidity advantage unless competitor’s new investments produce outsized returns.
No Data
No Data available this quarter, please select a different quarter.
169.66%
We have some outflow growth while AGEN is negative at -99.23%. John Neff sees competitor possibly pulling back more aggressively from minor expansions or intangible invests.
253.33%
We have mild expansions while AGEN is negative at -149.31%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
100.00%
Debt repayment above 1.5x AGEN's 7.56%, indicating stronger deleveraging. David Dodd would verify if expansions are not neglected.
-79.28%
Negative yoy issuance while AGEN is 2638.63%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.